Evoxac (Cevimeline Hydrochloride)

Evoxac (cevimeline hydrochloride) is used to treat the symptoms of dry mouth (xerostomia) in patients with Sjögren’s syndrome, an autoimmune condition that damages the salivary and tear glands. The usual dose is 30 mg three times a day.

Cevimeline stimulates muscarinic M1 and M3 receptors on the salivary glands, increasing the production of saliva and relieving the discomfort, difficulty swallowing and dental problems caused by a persistently dry mouth.

• Contraindicated in uncontrolled asthma, acute iritis and narrow-angle (angle-closure) glaucoma.
• Use with caution in patients with heart disease, controlled asthma, chronic bronchitis or COPD, kidney stones or gallstones.
• It can cause blurred vision, particularly at night; patients should be careful when driving at night.
• Common side effects include excessive sweating, nausea, runny nose and diarrhoea; drink extra fluids if sweating is heavy.

How can a patient in India get Evoxac?

Evoxac is an imported medicine and is not readily available through regular pharmacies in India. It can still be accessed legally on a named-patient basis, subject to Indian import regulations.

What do I need to provide?

• A valid prescription from a registered rheumatologist
• Report confirming Sjögren’s syndrome
• Patient ID proof issued by the Government of India

Is the order confirmed straight away?

No. We confirm it only once a valid prescription has been received and verified.

Indian Pharma Network (IPN) sources Evoxac through its authorised distribution network and arranges supply to patients, doctors and hospitals within the applicable legal framework.

For the current price of Evoxac in India and expected delivery time, call +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: FDA-approved in 2000 for dry mouth in Sjögren’s syndrome.
• Japan: Approved for dry mouth in Sjögren’s syndrome.

What does Evoxac treat?

It is a cholinergic (muscarinic) agonist, prescribed for dry mouth in patients with Sjögren’s syndrome.

Which company makes Evoxac?

Daiichi Sankyo.

How quickly does Evoxac work?

Saliva production usually increases within a few hours of a dose; regular dosing three times a day is needed for continued relief.

What is the mechanism of Evoxac?

Cevimeline stimulates muscarinic M1 and M3 receptors on the salivary glands, increasing the production of saliva and relieving the discomfort, difficulty swallowing and dental problems caused by a persistently dry mouth.

Does Evoxac have FDA approval?

Yes. Evoxac is FDA-approved for dry mouth in patients with Sjögren’s syndrome.